Research
Hormonal
The anti-inflammatory effect of marine-derived n-3 PUFAs on CRP is significantly weakened or absent in subjects with a BMI greater than 30 kg/m2.
If you have a BMI over 30, fish oil supplements may not significantly lower your CRP levels. Focus on weight management first, as the anti-inflammatory benefit of omega-3s is much less effective in obese individuals.
GoodQualifiesHIGH confidence
Restricted cubic spline analysis and subgroup analysis showed that the lowering effect of marine-derived n-3 PUFAs on CRP, IL-6 and TNF-a in subjects with chronic non-autoimmune disease became weakened when body mass index was greater than 30 kg/m2.
Why this rating
Based on subgroup analysis within a large meta-analysis.
Source
Effect of Marine-Derived n-3 Polyunsaturated Fatty Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α: A Meta-Analysis
Kelei Li et al. · PLoS ONE · 2014
DOI 10.1371/journal.pone.0088103
Meta-analysis · 68 studiesCited 226×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Marine-derived n-3 polyunsaturated fatty acid (PUFA) supplementation significantly lowers fasting blood levels of C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) in subjects with chronic non-autoimmune disease, chronic autoimmune disease, and healthy subjects.Good
- Longer duration of marine-derived n-3 PUFAs supplementation leads to a greater lowering effect on IL-6 and TNF-α in subjects with chronic non-autoimmune disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →